PharVision Advisers’s Synaptics SYNA Stock Holding History

PharVision Advisers’s Portfolio SYNA Stock Details SYNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,352	Closed	-$217K	–	793
2025 Q2	$217K	Buy	+3,352	New	+$197K	0.31%	179

Other funds holding SYNA

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

PharVision Advisers's SYNA Position: Q3 2025 in Review

PharVision Advisers sold out of Synaptics (SYNA) in Q3 2025, closing a stake of 3,352 shares — an estimated $217K sold.

PharVision Advisers first reported a position in SYNA in Q2 2025 and held it in 1 quarter. The position peaked at $217K in Q2 2025. 291 funds tracked by Wall St. Rank hold SYNA as of Q3 2025.

PharVision Advisers reported no remaining Synaptics position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 3,352 Synaptics shares in Q3 2025, an estimated $217K.
PharVision Advisers first reported a position in Synaptics in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Synaptics position peaked at $217K in Q2 2025.
291 funds tracked by Wall St. Rank held Synaptics as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.